KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAssetsCapital LeasesCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityMinority InterestNon-Current AssetsNon-Current DebtOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShares OutstandingShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Amneal Pharmaceuticals (AMRX) Notes Payables (2018 - 2024)

Amneal Pharmaceuticals has reported Notes Payables over the past 5 years, most recently at $41.9 million for Q1 2024.

  • For Q1 2024, Notes Payables changed N/A year-over-year to $41.9 million; the TTM value through Mar 2024 reached $41.9 million, changed N/A, while the annual FY2023 figure was $41.4 million, 4.38% up from the prior year.
  • Notes Payables for Q1 2024 was $41.9 million at Amneal Pharmaceuticals, up from $41.4 million in the prior quarter.
  • Over five years, Notes Payables peaked at $41.9 million in Q1 2024 and troughed at $1.0 million in Q1 2020.
  • A 4-year average of $23.2 million and a median of $39.7 million in 2022 define the central range for Notes Payables.
  • On a YoY basis, Notes Payables climbed as much as 4.38% in 2023 and fell as far as 4.38% in 2023.
  • Year by year, Notes Payables stood at $1.0 million in 2020, then soared by 3870.6% to $39.7 million in 2022, then grew by 4.38% to $41.4 million in 2023, then rose by 1.08% to $41.9 million in 2024.
  • Business Quant data shows Notes Payables for AMRX at $41.9 million in Q1 2024, $41.4 million in Q4 2023, and $41.0 million in Q3 2023.